AbbVie Inc. (NYSE:ABBV) Holdings Cut by Fort Sheridan Advisors LLC
AbbVie Inc. (NYSE:ABBV) Holdings Cut by Fort Sheridan Advisors LLC
Fort Sheridan Advisors LLC lowered its holdings in AbbVie Inc. (NYSE:ABBV – Get Rating) by 6.0% during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 20,566 shares of the company's stock after selling 1,313 shares during the period. AbbVie comprises about 1.0% of Fort Sheridan Advisors LLC's investment portfolio, making the stock its 21st biggest holding. Fort Sheridan Advisors LLC's holdings in AbbVie were worth $3,334,000 as of its most recent filing with the Securities & Exchange Commission.
Fort Sheridan Advisors LLC向美國證券交易委員會提交的最新Form 13F文件顯示,該公司第一季度減持艾伯維公司股份6.0%。該基金在此期間出售了1,313股後,持有該公司20,566股股票。AbbVie在Fort Sheridan Advisors LLC的投資組合中約佔1.0%,使該股成為其第21大持股。截至最近提交給美國證券交易委員會(Securities&Exchange Commission)的文件,Fort Sheridan Advisors LLC持有的AbbVie股份價值333.4萬美元。
A number of other large investors have also recently bought and sold shares of the business. Norges Bank acquired a new stake in shares of AbbVie in the fourth quarter valued at approximately $2,433,269,000. State Street Corp increased its stake in shares of AbbVie by 3.4% in the fourth quarter. State Street Corp now owns 79,357,705 shares of the company's stock valued at $10,745,033,000 after purchasing an additional 2,597,076 shares during the period. Capital International Investors increased its stake in shares of AbbVie by 19.7% during the fourth quarter. Capital International Investors now owns 11,615,068 shares of the company's stock valued at $1,572,680,000 after acquiring an additional 1,913,451 shares during the period. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main increased its stake in shares of AbbVie by 51.2% during the fourth quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 5,533,034 shares of the company's stock valued at $752,074,000 after acquiring an additional 1,874,609 shares during the period. Finally, Nuveen Asset Management LLC increased its stake in shares of AbbVie by 12.2% during the fourth quarter. Nuveen Asset Management LLC now owns 16,331,749 shares of the company's stock valued at $2,211,319,000 after acquiring an additional 1,771,090 shares during the period. Institutional investors own 67.03% of the company's stock.
其他一些大型投資者最近也買賣了該公司的股票。挪威銀行在第四季度收購了AbbVie的新股份,價值約2,433,269,000美元。道富集團在第四季度增持了3.4%的艾伯維股票。道富銀行目前持有79,357,705股該公司股票,價值10,745,033,000美元,在此期間又購買了2,597,076股。Capital International Investors在第四季度增持了19.7%的AbbVie股票。Capital International Investors在此期間增持了1,913,451股,目前擁有11,615,068股該公司股票,價值1,572,680,000美元。DZ Bank AG Deutsche Zentral Genosenschaft Bank Frankfort am Main在第四季度增加了對AbbVie股票的持股51.2%。DZ銀行股份公司在此期間增持了1,874,609股後,現在擁有5,533,034股公司股票,價值752,074,000美元。最後,Nuveen Asset Management LLC在第四季度將其在AbbVie股票中的持股增加了12.2%。Nuveen Asset Management LLC在此期間額外收購了1,771,090股,現在擁有16,331,749股該公司的股票,價值2,211,319,000美元。機構投資者持有該公司67.03%的股份。
Insider Buying and Selling at AbbVie
艾伯維的內幕買賣
In other news, EVP Henry O. Gosebruch sold 83,960 shares of the stock in a transaction dated Monday, May 16th. The shares were sold at an average price of $155.00, for a total value of $13,013,800.00. Following the transaction, the executive vice president now directly owns 16,623 shares of the company's stock, valued at $2,576,565. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, Vice Chairman Michael Severino sold 100,000 shares of the stock in a transaction dated Monday, May 16th. The shares were sold at an average price of $154.45, for a total value of $15,445,000.00. Following the transaction, the insider now directly owns 152,103 shares of the company's stock, valued at $23,492,308.35. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Henry O. Gosebruch sold 83,960 shares of the stock in a transaction dated Monday, May 16th. The shares were sold at an average price of $155.00, for a total transaction of $13,013,800.00. Following the completion of the transaction, the executive vice president now directly owns 16,623 shares in the company, valued at $2,576,565. The disclosure for this sale can be found here. Insiders sold a total of 363,761 shares of company stock worth $55,528,771 over the last quarter. 0.08% of the stock is currently owned by insiders.
在其他新聞方面,執行副總裁亨利·O·古斯布魯赫在5月16日星期一的交易中出售了83,960股該公司股票。這些股票的平均價格為155.00美元,總價值為13,013,800.00美元。交易完成後,執行副總裁總裁現在直接持有該公司16,623股股票,價值2576,565美元。這筆交易是在提交給美國證券交易委員會的一份法律文件中披露的,該文件可在美國證券交易委員會網站上查閲。在其他新聞方面,副董事長邁克爾·塞維裏諾在5月16日星期一的交易中出售了10萬股該公司股票。這些股票的平均價格為154.45美元,總價值為15,445,000.00美元。交易完成後,這位內部人士現在直接擁有152,103股該公司股票,價值23,492,308.35美元。這筆交易是在提交給美國證券交易委員會的一份法律文件中披露的,該文件可在美國證券交易委員會網站上查閲。此外,執行副總裁亨利·O·古斯布魯赫在5月16日星期一的交易中出售了83,960股該股。這些股票以155.00美元的平均價格出售,總成交金額為13,013,800.00美元。交易完成後,執行副總裁總裁現在直接持有該公司16,623股股份,價值2,576,565美元。此次拍賣的披露信息可在此處找到。在上個季度,內部人士總共出售了363,761股公司股票,價值55,528,771美元。目前該公司0.08%的股份由內部人士持有。
Analyst Ratings Changes
分析師評級發生變化
AbbVie Stock Down 0.6 %
艾伯維股價下跌0.6%
Shares of ABBV stock opened at $138.04 on Friday. The firm has a fifty day moving average of $147.52 and a 200-day moving average of $150.06. The company has a quick ratio of 0.71, a current ratio of 0.82 and a debt-to-equity ratio of 3.89. AbbVie Inc. has a 12-month low of $105.56 and a 12-month high of $175.91. The company has a market capitalization of $243.93 billion, a price-to-earnings ratio of 19.55, a P/E/G ratio of 3.90 and a beta of 0.70.
上週五,ABBV股票開盤報138.04美元。該公司的50日移動均線切入位在147.52美元,200日移動均線切入位在150.06美元。該公司的速動比率為0.71,流動比率為0.82,債務權益比為3.89。艾伯維公司的股價為105.56美元的12個月低點和175.91美元的12個月高位。該公司市值為2,439.3億美元,市盈率為19.55倍,市盈率為3.90倍,貝塔係數為0.70。
AbbVie (NYSE:ABBV – Get Rating) last announced its earnings results on Friday, July 29th. The company reported $3.37 EPS for the quarter, topping the consensus estimate of $3.31 by $0.06. AbbVie had a net margin of 22.03% and a return on equity of 157.31%. The business had revenue of $14.58 billion during the quarter, compared to analysts' expectations of $14.64 billion. During the same quarter in the prior year, the company posted $3.11 earnings per share. The firm's revenue was up 4.5% on a year-over-year basis. As a group, equities research analysts predict that AbbVie Inc. will post 14.05 earnings per share for the current fiscal year.
艾伯維(紐約證券交易所代碼:ABBV-GET Rating)上一次公佈財報是在7月29日星期五。該公司公佈本季度每股收益為3.37美元,比普遍預期的3.31美元高出0.06美元。艾伯維的淨利潤率為22.03%,股本回報率為157.31%。該業務當季營收為145.8億美元,高於分析師預期的146.4億美元。去年同期,該公司公佈的每股收益為3.11美元。該公司的收入同比增長了4.5%。股票研究公司分析師預計,艾伯維公司本財年的每股收益將達到14.05美元。
AbbVie Dividend Announcement
AbbVie股息公告
The company also recently declared a quarterly dividend, which will be paid on Monday, August 15th. Shareholders of record on Friday, July 15th will be paid a $1.41 dividend. This represents a $5.64 dividend on an annualized basis and a yield of 4.09%. The ex-dividend date is Thursday, July 14th. AbbVie's dividend payout ratio is currently 79.89%.
該公司最近還宣佈了季度股息,將於8月15日(星期一)支付。7月15日(星期五)登記在冊的股東將獲得1.41美元的股息。這意味着年化股息為5.64美元,收益率為4.09%。除股息日期為7月14日星期四。艾伯維的股息支付率目前為79.89%。
About AbbVie
關於AbbVie
(Get Rating)
(獲取評級)
AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection.
艾伯維公司在世界各地發現、開發、製造和銷售藥品。該公司提供HUMIRA,用於注射治療自身免疫和腸道Behçet‘s疾病;SKYRIZI用於治療成人中到重度斑塊型牛皮癬;RINVOQ,用於治療成人患者的中到重度活動性類風濕性關節炎;IMBRUVICA,用於治療成人慢性淋巴細胞白血病和小淋巴細胞淋巴瘤;以及VENCLEXTA,用於治療成人慢性丙型肝炎病毒基因1-6感染。
Further Reading
進一步閲讀
- Get a free copy of the StockNews.com research report on AbbVie (ABBV)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc's Revenues Are Up, Is It Time to Buy?
- Why Apple Could Be At All-Time Highs By Year End
- Beyond Meat Is Not Beyond Hope, And It's Cheap
- 免費獲取StockNews.com關於AbbVie的研究報告(ABBV)
- MarketBeat:回顧中的一週8/1-8/5
- 如何利用高貝塔係數股票最大化你的投資利潤
- 克羅諾斯集團(Cronos Group Inc.)營收上升,是時候收購了嗎?
- 蘋果為何可能在年底創下歷史新高
- Beyond Meat不是沒有希望,而且它很便宜
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.
接收AbbVie Daily的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對AbbVie和相關公司的最新新聞和分析師評級的每日簡要摘要。
譯文內容由第三人軟體翻譯。